title: Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group.
authors.affiliation: Department of Paediatric Oncology, Institut Gustave Roussy, Villejuif, France.
authors.forename: Walter Daniel
authors.initials: WD
authors.lastname: Cacciavillano
authors.forename: Laurence
authors.initials: L
authors.lastname: Brugières
authors.forename: Margaret
authors.initials: M
authors.lastname: Childs
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Shafford
authors.forename: Penelope
authors.initials: P
authors.lastname: Brock
authors.forename: Jon
authors.initials: J
authors.lastname: Pritchard
authors.forename: Rudolf
authors.initials: R
authors.lastname: Mailbach
authors.forename: Marcello
authors.initials: M
authors.lastname: Scopinaro
authors.forename: Giorgio
authors.initials: G
authors.lastname: Perilongo
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D018197:Hepatoblastoma / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin